TheraRadar
← Back
Data updated: Jun 28, 2026

HAUN SPECIALTY GASES INC

Pharma
Pharmaceuticals

HAUN SPECIALTY GASES INC is a pharmaceutical company with 1 FDA-approved products.

2024
Since
1
Drugs
-
Trials
6
New Drugs (2yr)
Modality:
1 Small Molecules

HAUN SPECIALTY GASES INC's Key Drugs

HAUN SPECIALTY GASES INC's core commercial portfolio centers on CARBON DIOXIDE, USP — its most strategically important drugs approved in the last 15 years.

CARBON DIOXIDE, USP
Respiratory
Approved 2013

HAUN SPECIALTY GASES INC's Recent FDA Approvals

HAUN SPECIALTY GASES INC secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

CARBON DIOXIDE, USP NDA
2025-10-25
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21
carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02
carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09
carbon dioxide, usp
CARBON DIOXIDE, USP NDA
2024-08-10
carbon dioxide

HAUN SPECIALTY GASES INC's Therapeutic Areas

Disease areas where HAUN SPECIALTY GASES INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

HAUN SPECIALTY GASES INC Pipeline Snapshot

Active clinical trials for HAUN SPECIALTY GASES INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • CARBON DIOXIDE, USP leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling